항균제 감수성 시험 : 시장 인사이트, 경쟁 구도 및 시장 예측(2034년)

Antimicrobial Susceptibility Testing Market Summary

Overview:

• The global antimicrobial susceptibility testing market was valued at USD 4,128.15 million in 2025 and is projected to reach USD 6,475.48 million by 2034.
• The market is expected to expand at a CAGR of 5.18% during the forecast period 2026-2034, supported by the escalating threat of antimicrobial resistance, the rising burden of infectious disease and sepsis, and the growth of antimicrobial stewardship programs.
• By product, the manual products segment dominated the antimicrobial susceptibility testing market with a 45% share in 2025.
• By method type, the disk diffusion segment dominated the antimicrobial susceptibility testing market with a 34% share in 2025.
• By test type, the antibacterial testing segment dominated the antimicrobial susceptibility testing market with a 68% share in 2025.
• By application, the clinical diagnostics segment dominated the antimicrobial susceptibility testing market with a 55% share in 2025.
• By end-user, the hospitals and diagnostic laboratories segment dominated the antimicrobial susceptibility testing market with a 60% share in 2025.
• North America accounted for the largest share of the antimicrobial susceptibility testing market at 38% in 2025, while Asia-Pacific is anticipated to register the fastest growth through 2034.

Antimicrobial susceptibility testing is the laboratory determination of the susceptibility or resistance of a microorganism to the antimicrobial agents used to treat it, guiding clinicians in the selection of effective therapy and supporting the surveillance and stewardship that combat antimicrobial resistance. The market is organized by the product supplied, the method employed, the type of test, the application, and the setting of use. By product, it divides into manual products, automated products, and consumables, with the manual products holding the largest share. By method, it spans disk diffusion, broth and agar dilution for the determination of the minimum inhibitory concentration, gradient diffusion, automated testing, and molecular methods. By test type it divides among antibacterial, antifungal, and antiparasitic testing, and by application among clinical diagnostics, drug discovery and development, and epidemiology. By end-user, it spans hospitals and diagnostic laboratories, pharmaceutical and biotechnology companies, and academic and research institutes. The market is driven above all by the escalating global threat of antimicrobial resistance, which makes the accurate and timely determination of susceptibility essential to the selection of effective therapy and to the stewardship that preserves the effectiveness of antimicrobials, and by the rising burden of infectious disease and sepsis, the growth of stewardship programs, and the migration toward the rapid and automated testing that accelerates the delivery of results.

Antimicrobial Susceptibility Testing Market Key Growth Drivers

• The escalating global threat of antimicrobial resistance, identified by the World Health Organization as a top global health threat, with some 1.3 million deaths attributable to bacterial antimicrobial resistance each year, making susceptibility testing essential to guiding effective therapy.
• The rising burden of infectious disease and sepsis, with some 11 million sepsis deaths worldwide each year, increases the demand for rapid and accurate susceptibility testing that guides treatment.
• The growth of antimicrobial stewardship programs and infection control mandates, which depend upon susceptibility testing to guide appropriate antibiotic use and to combat the spread of resistant organisms.
• Continuous technological advancement, including rapid phenotypic susceptibility testing directly from positive blood cultures, laboratory automation, and molecular and mass-spectrometry methods that accelerate the delivery of results.
• The rising incidence of hospital-acquired infections and of multidrug-resistant organisms, which increases the volume and the complexity of susceptibility testing.
• Government initiatives, funding, and regulatory support for the diagnosis and surveillance of antimicrobial resistance, including breakthrough device designations and stewardship mandates.
• The growing demand of the pharmaceutical and biotechnology industries for susceptibility testing in the discovery and development of new antimicrobials.

Key Companies in Antimicrobial Susceptibility Testing Market

The competitive landscape is led by the following active manufacturers:

• bioMerieux SA
• Becton, Dickinson and Company
• Thermo Fisher Scientific Inc.
• Danaher Corporation (Beckman Coulter)
• Bruker Corporation
• Merck KGaA
• HiMedia Laboratories Pvt. Ltd.
• Liofilchem S.r.l.
• Accelerate Diagnostics, Inc.
• Bio-Rad Laboratories, Inc.

Factors Contributing to the Growth of the Antimicrobial Susceptibility Testing Market

Market Drivers

Escalating Threat of Antimicrobial Resistance

The foundational driver of the antimicrobial susceptibility testing market is the escalating global threat of antimicrobial resistance, because the response to resistance depends upon the determination of which antimicrobials remain effective against a given organism, which is the defining function of susceptibility testing. Antimicrobial resistance, in which bacteria, fungi, and other microorganisms evolve to withstand the drugs used to treat them, has been identified by the World Health Organization as one of the top threats to global health, and some 1.3 million deaths each year are attributable to bacterial antimicrobial resistance, with millions more associated with it. The clinical and public health response to this threat rests upon susceptibility testing, since the effective treatment of a resistant infection requires the identification of which antimicrobials the organism remains susceptible to, and the stewardship and surveillance programs that seek to preserve the effectiveness of antimicrobials depend upon the susceptibility data that testing provides. As resistance rises and spreads, the empirical selection of therapy becomes less reliable, and the need for the accurate, organism-specific susceptibility information that testing provides increases; the emergence of multidrug-resistant and extensively drug-resistant organisms makes susceptibility testing indispensable to identifying the few remaining effective agents. Because antimicrobial resistance is a large, rising, and urgent global threat, and because susceptibility testing is central to the clinical and public health response to it, this driver provides the most durable foundation for market growth.

Rising Burden of Infectious Disease and Sepsis

The rising burden of infectious disease and sepsis is a powerful driver of the antimicrobial susceptibility testing market, because the volume of serious infections that require susceptibility-guided therapy determines the demand for testing, and sepsis in particular creates urgent demand for rapid results. The burden of the bloodstream, respiratory, urinary, and other serious bacterial infections that require susceptibility testing to guide therapy is very large and rising, driven by aging, the growth of the immunocompromised population, and the rising prevalence of resistant organisms, and sepsis, the life-threatening organ dysfunction caused by a dysregulated response to infection, imposes an enormous burden, with some 11 million sepsis deaths worldwide each year. In sepsis and other serious infections, the rapid and accurate determination of susceptibility is critical, since prolonged empirical broad-spectrum therapy while awaiting conventional results increases the risk of adverse effects, promotes resistance, and delays the optimization of treatment, and the demand for rapid susceptibility testing that shortens this window is a particularly strong driver. The rising burden of the infections that require testing, and the recognition of the value of rapid, targeted therapy, together increase both the volume and the urgency of susceptibility testing. Because the burden of serious infection and sepsis is large, rising, and dependent upon susceptibility testing, this driver is a powerful contributor to market growth.

Market Restraints

Despite an escalating threat of antimicrobial resistance and rapid technological advances, the antimicrobial susceptibility testing market faces several material constraints. The most significant is the slow turnaround of the conventional culture-based methods that constitute the majority of testing, since these methods depend upon the growth of the organism and require a day or more to yield results, delaying the optimization of therapy, and although rapid phenotypic and molecular methods address this limitation, they carry higher costs and have not displaced the conventional methods, which remain the reference standard and the majority of testing. A second constraint is the high cost of the rapid and automated systems, since the advanced instruments that accelerate and automate susceptibility testing carry substantial acquisition and operating costs that restrict their adoption, particularly among smaller laboratories and providers in emerging markets, and the recurring cost of the consumables and panels adds to the total cost of ownership, so that the cost of the advanced methods constrains their diffusion even as their clinical value is recognized. A third constraint is the shortage of skilled microbiologists and laboratory technicians able to perform and interpret susceptibility testing, which is a specialized discipline requiring training and expertise, and the limited availability of qualified personnel constrains both the capacity and the quality of testing, particularly in emerging markets. Additional constraints include the complexity and continual evolution of the breakpoints that define susceptibility and resistance, which require laboratories to update their methods and panels as standards change; the difficulty of susceptibility testing for the fastidious, slow-growing, and difficult-to-culture organisms; the pressure of reimbursement and laboratory budgets; and the regulatory requirements governing diagnostic devices. Together, these turnaround, cost, workforce, and standardization factors ensure that growth, while steady, proceeds against genuine constraint.

Antimicrobial Susceptibility Testing Market Segment Analysis

The antimicrobial susceptibility testing market by product (manual products, automated products, and consumables), method type (disk diffusion, dilution, gradient diffusion, automated testing, and others), test type (antibacterial, antifungal, and antiparasitic testing), application (clinical diagnostics, drug discovery and development, and epidemiology), end-user (hospitals and diagnostic laboratories, pharmaceutical and biotechnology companies, and academic and research institutes), and geography (North America, Europe, Asia-Pacific, and the Rest of the World).

By Product

Dominant Subsegment: Manual Products.

The manual products segment accounted for a 45% share of the antimicrobial susceptibility testing market in 2025. Manual products dominate the product structure because of the ease of availability and the lower cost of manual susceptibility testing relative to automated testing, and because the disk diffusion, gradient diffusion, and dilution methods that manual products enable remain the widely used and reference-standard methods of the microbiology laboratory. Manual products, including the antimicrobial disks, gradient diffusion strips, and dilution media and panels used to perform susceptibility testing by hand, are inexpensive, flexible, and broadly applicable, and they allow laboratories to test any organism against any panel of antimicrobials without the capital cost of automated instruments, sustaining their leading share, particularly in the cost-sensitive and lower-volume settings and in the emerging markets. The consumables consumed by both manual and automated testing, including the disks, strips, panels, and media, represent a large and recurring source of demand tied to test volume. The automated products segment, comprising the automated susceptibility testing instruments that improve throughput, consistency, and speed, constitutes the fastest-growing category, projected to grow at the highest rate as laboratories adopt automation to address rising volumes, the shortage of skilled personnel, and the demand for faster results, and the rapid phenotypic systems that report results directly from positive blood cultures are a particularly dynamic part of it. The manual products segment is expected to retain its leading share throughout the forecast period, while automated products grow fastest.

By Method Type

Dominant Subsegment: Disk Diffusion.

The disk diffusion segment accounted for a 34% share of the antimicrobial susceptibility testing market in 2025. Disk diffusion dominates the method structure owing to its flexibility, cost-effectiveness, and simplicity, which have made it the most widely used method of susceptibility testing in laboratories worldwide. In the disk diffusion method, antimicrobial-impregnated disks are placed on an agar plate inoculated with the organism, and the zone of inhibition of growth surrounding each disk is measured to determine susceptibility; the method is inexpensive, requires no specialized instruments, applies to a wide range of organisms and antimicrobials, and is standardized by international standard-setting bodies, sustaining its leading position. The low cost and flexibility of disk diffusion make it especially prevalent in cost-sensitive and lower-volume laboratories and in emerging markets, and its standardization and long clinical track record reinforce its use. Dilution methods, which determine the minimum inhibitory concentration through broth or agar dilution, constitute a substantial category valued for the quantitative result they provide, and gradient diffusion, which combines the simplicity of diffusion with a quantitative minimum inhibitory concentration result, constitutes a further important method. Automated testing, in which instruments perform and read the susceptibility test, constitutes the fastest-growing method, driven by the demand for throughput, consistency, and speed, and molecular and other methods complete the structure. Disk diffusion is expected to retain its leading share throughout the forecast period, while automated methods grow fastest.

Antimicrobial Susceptibility Testing Market Region Analysis

Dominant Region: North America

North America accounted for a 38% share of the global antimicrobial susceptibility testing market in 2025. The region is expected to account for the largest share of the global market, driven by the high prevalence and awareness of antimicrobial resistance, the strong adoption of advanced and rapid testing, well-developed reimbursement and healthcare infrastructure, federal initiatives promoting antimicrobial stewardship, and the presence and commercial strength of the leading diagnostics companies. The United States hosts a large and technologically advanced network of hospitals and clinical laboratories that perform a very high volume of susceptibility testing and are early adopters of the rapid phenotypic, automated, and molecular methods that define the modern field, and the strong reimbursement environment and high healthcare expenditure support the investment these systems require. The region leads in the response to antimicrobial resistance, with federal initiatives promoting antimicrobial stewardship strengthening demand, in the regulatory support for rapid diagnostics, including breakthrough device designations, and in the presence of the leading diagnostics manufacturers and strong research activity that support innovation. The high volume of testing in acute care settings ensures consistent utilization, and the regulatory support and clinical necessity keep the outlook robust. The region is expected to retain its leading position throughout the forecast period.

Fastest Growing Region: Asia-Pacific

Asia-Pacific is projected to register the fastest compound annual growth rate in the antimicrobial susceptibility testing market through 2034. The region is emerging as the principal growth engine of the market, propelled by very large populations, a high and rising burden of infectious disease and antimicrobial resistance, expanding healthcare access and laboratory infrastructure, rising healthcare expenditure, and increasing government initiatives against resistance across China, India, Japan, and Southeast Asia. The region combines the largest populations in the world with a high burden of bacterial infection and the antimicrobial resistance that susceptibility testing addresses, and the burden of resistance is particularly acute in parts of the region where antimicrobial use has been high and testing capacity limited. The expansion and modernization of diagnostic laboratory infrastructure, driven by rising incomes, expanding healthcare access, and growing public and private investment, is converting this burden into demand for testing, and governments are increasingly implementing national action plans, surveillance systems, and stewardship programs against resistance that require susceptibility testing. China combines a very large population with a rapidly developing diagnostics industry and is expected to register among the highest growth; India combines a very large population and infection burden with a rapidly expanding diagnostic laboratory sector, and Japan combines an advanced healthcare system with sophisticated testing. Regional growth is expected to exceed the global average across every segment.

Regional Commentary

North America

North America leads on value and adoption, holding a 38% share in 2025. The region combines a high burden and awareness of antimicrobial resistance, strong adoption of advanced and rapid testing, well-developed reimbursement and infrastructure, federal stewardship initiatives, and the commercial strength of the leading diagnostics companies. It leads in the response to resistance, in the regulatory support for rapid diagnostics, and in the high-volume testing of acute care. Near-term dynamics are shaped by the migration to rapid phenotypic and automated testing, the expansion of stewardship, the updating of breakpoints, and the response to multidrug-resistant organisms.

Europe

Europe is a large and sophisticated market, and the home region of several of the leading companies, including a major in vitro diagnostics leader, and it combines well-developed healthcare systems, strong stewardship and surveillance infrastructure, and the influential European breakpoint standards, with Germany, France, the United Kingdom, and Italy as principal markets. The region combines a substantial burden of infection and resistance with generally supportive public healthcare and a strong regulatory and public health emphasis upon antimicrobial resistance, and the European standard-setting body that establishes susceptibility breakpoints is highly influential. The In Vitro Diagnostic Medical Devices Regulation shapes the introduction of new tests, and the region sustains a competitive and advanced market served by both global and regional participants.

Asia-Pacific

Asia-Pacific is the fastest-growing region, propelled by very large populations, a high and rising burden of infection and antimicrobial resistance, expanding healthcare access and laboratory infrastructure, rising healthcare expenditure, and increasing government initiatives against resistance. The modernization of laboratory infrastructure is converting the large burden of resistance into demand for testing. China combines a very large population with a developing diagnostics industry and is expected to register among the highest growth; India combines a very large population and infection burden with a rapidly expanding laboratory sector, and Japan combines an advanced system with sophisticated testing. Both international and regional companies are expanding across the advanced and cost-effective segments. Growth exceeds the global average across every segment.

Rest of World

The Rest of the World comprises the Middle East, Africa, and South America. The burden of infection and antimicrobial resistance is high across all three, and the region carries a substantial and rising demand for susceptibility testing, with resistance a particular concern where antimicrobial use has been high and testing capacity limited. The Gulf states combine high healthcare investment with advanced laboratory infrastructure, and the larger Latin American markets, particularly Brazil, support established diagnostic laboratory sectors and growing adoption of advanced testing, together representing steady growth. Much of Africa carries a very high infection and resistance burden but faces severe constraints in laboratory infrastructure, personnel, and funding, so testing capacity is concentrated in the larger urban, private, and public health laboratories, with substantial unmet need. Regional growth will be driven by the high burden, expanding infrastructure, strengthening surveillance, and the availability of cost-appropriate testing.

Antimicrobial Susceptibility Testing Market Competitive Landscape

The global antimicrobial susceptibility testing market is classified as Moderately Concentrated. The market is led by a group of large diversified diagnostics and life-science companies with established susceptibility testing systems, consumables, and global reach, complemented by specialized microbiology and rapid-testing firms. Competition centers upon the breadth and standardization of the testing menu, the speed of results, the degree of automation, the installed base and its recurring consumable revenue, integration with identification and laboratory information systems, and increasingly upon rapid phenotypic testing and the response to antimicrobial resistance. The competitive landscape is evaluated across the following dimensions:

• Market concentration: Moderately concentrated, with a group of large diversified diagnostics and life-science companies holding significant combined share across the manual, automated, and consumable segments alongside specialized microbiology and rapid-testing firms, and with the installed base, menu breadth, standardization, and regulatory capability of the leaders constituting a barrier to entry.
• Leading players: bioMerieux leads the field through its comprehensive identification and susceptibility portfolio, including automated and rapid phenotypic systems, with Becton Dickinson strong in automated susceptibility and molecular testing, Thermo Fisher and Danaher through Beckman Coulter strong in automated and manual systems, Bruker in mass-spectrometry-based methods, and Merck, HiMedia, Liofilchem, and Bio-Rad in consumables and manual products, alongside specialized rapid-testing firms including Accelerate Diagnostics, Q-linea, and Selux Diagnostics.
• Geographic reach: The leading participants maintain global commercial, distribution, and service organizations, decisive because susceptibility testing is a global market requiring local sales, service, and regulatory presence, while specialized firms reach broader geographies through distribution, and regional manufacturers serve domestic and cost-sensitive markets, particularly across Asia-Pacific.
• Product portfolio strength: Competitive advantage rests upon offering a broad and standardized testing menu spanning manual and automated methods, upon the speed of results, upon the automation that improves throughput and consistency, and upon the installed base that generates recurring consumable revenue, with the leaders competing on comprehensive and integrated identification and susceptibility solutions and specialized firms on a superior rapid phenotypic technology.
• Pipeline strength: Development is concentrated in rapid phenotypic susceptibility testing directly from positive blood cultures, laboratory automation, molecular and genotypic resistance detection, expanded and updated antimicrobial panels, and the integration of susceptibility testing with identification and stewardship systems.
• Strategic partnerships: Collaboration spans partnerships between diagnostics companies and hospitals, laboratories, and stewardship programs, the integration of susceptibility testing with identification, molecular, and laboratory information systems, and co-development and the acquisition of rapid-testing capability, exemplified by the acquisition of a rapid phenotypic testing company by a leading diagnostics firm.
• M&A activity: Acquisition and consolidation have shaped the field, including the acquisition of rapid phenotypic and molecular testing capability by the diversified leaders, exemplified by the acquisition of a rapid antimicrobial susceptibility testing company and the integration of its technology into a comprehensive sepsis and susceptibility portfolio.
• Innovation focus: Innovation is shifting toward rapid phenotypic testing that delivers susceptibility results directly from positive blood cultures in hours, laboratory automation that addresses throughput and personnel constraints, molecular and genotypic resistance detection, artificial intelligence in interpretation, and the integration of susceptibility testing with identification and stewardship.
• Regulatory standing: Regulatory clearance and approval for diagnostic devices in the major jurisdictions, including United States Food and Drug Administration clearance and CE marking, together with the breakthrough device designations that expedite the review of high-value rapid systems, are decisive credentials, and the standardization of susceptibility testing by the international breakpoint-setting bodies both governs the market and rewards the standardization and regulatory capability of the leading companies.

Antimicrobial Susceptibility Testing Market Recent Developmental Activities

In June 2024, bioMerieux received United States Food and Drug Administration 510(k) clearance for its VITEK REVEAL antimicrobial susceptibility testing system, which reports phenotypic susceptibility results for Gram-negative bacteria directly from positive blood cultures in an average of some five and a half hours, enabling same-day treatment decisions in bacteremic sepsis. Strategic significance: the clearance of a rapid phenotypic system reporting directly from positive blood cultures addressed the central limitation of conventional susceptibility testing, its slow turnaround, in the urgent setting of sepsis, and reinforced the migration of the market toward rapid, actionable results that support antimicrobial stewardship.

Antimicrobial Susceptibility Testing Market Segmentation

Antimicrobial Susceptibility Testing Market Assessment by Product

• Manual Products
• Automated Products
• Consumables

Antimicrobial Susceptibility Testing Market Assessment by Method Type

• Disk Diffusion
• Dilution
• Gradient Diffusion
• Automated Testing
• Others

Antimicrobial Susceptibility Testing Market Assessment by Test Type

• Antibacterial
• Antifungal
• Antiparasitic

Antimicrobial Susceptibility Testing Market Assessment by Application

• Clinical Diagnostics
• Drug Discovery and Development
• Epidemiology

Antimicrobial Susceptibility Testing Market Assessment by End-User

• Hospitals and Diagnostic Laboratories
• Pharmaceutical and Biotechnology Companies
• Academic and Research Institutes

Antimicrobial Susceptibility Testing Market Assessment by Geography

• North America
• United States Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
• Canada Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
• Mexico Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
• Europe
• France Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
• Germany Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
• United Kingdom Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
• Italy Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
• Spain Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
• Rest of Europe Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
• Asia-Pacific
• China Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
• Japan Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
• India Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
• Australia Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
• South Korea Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
• Rest of Asia-Pacific Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
• Rest of the World
• Middle East Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
• Africa Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
• South America Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)

Key Takeaways from the Antimicrobial Susceptibility Testing Market Report Study

• Market size analysis for the current Antimicrobial Susceptibility Testing market size (2025), and market forecast for 9 years (2026 to 2034).
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that have happened over the last 3 years.
• Key companies dominating the global Antimicrobial Susceptibility Testing market.
• Various opportunities available for competitors in the Antimicrobial Susceptibility Testing market space.
• What are the top-performing segments in 2025? How will these segments perform in 2034?
• Which are the top-performing regions and countries in the current Antimicrobial Susceptibility Testing market scenario?
• Which are the regions and countries where companies should concentrate their opportunities for Antimicrobial Susceptibility Testing market growth in the future?

Target audience who can benefit from this Antimicrobial Susceptibility Testing market report study

• Antimicrobial Susceptibility Testing product providers
• Research organizations and consulting companies
• Antimicrobial Susceptibility Testing -related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in Antimicrobial Susceptibility Testing
• Various end-users who want to know more about the Antimicrobial Susceptibility Testing market and the latest technological developments in the Antimicrobial Susceptibility Testing market.

Frequently Asked Questions:

Q1. At what rate is the antimicrobial susceptibility testing market expected to grow?

The global antimicrobial susceptibility testing market is projected to grow at a compound annual growth rate of 5.18% during the forecast period from 2026 to 2034.

Q2. What is the current and projected size of the antimicrobial susceptibility testing market?

The global antimicrobial susceptibility testing market was valued at USD 4,128.15 million in 2025 and is projected to reach USD 6,475.48 million by 2034.

Q3. Which region dominates the antimicrobial susceptibility testing market?

North America dominated the antimicrobial susceptibility testing market with a 38% share in 2025 on a modeled basis, driven by the high burden and awareness of antimicrobial resistance, strong adoption of advanced and rapid testing, well-developed reimbursement and infrastructure, federal initiatives promoting antimicrobial stewardship, and the presence of the leading diagnostics companies. Asia-Pacific is projected to record the fastest compound annual growth rate through 2034, driven by very large populations, a high and rising burden of infection and resistance, expanding healthcare access and laboratory infrastructure, and increasing government initiatives across China, India, Japan, and Southeast Asia.

Table of Contents

1. Antimicrobial Susceptibility Testing Market Introduction

• 1.1. Scope of the Report
• 1.2. Market Segmentation
• 1.3. Market Overview at a Glance

2. Antimicrobial Susceptibility Testing Market Executive Summary

• 2.1. Key Highlights and Market Snapshot

3. Antimicrobial Susceptibility Testing Market Key Factors Analysis

• 3.1. Market Drivers
  • 3.1.1. Escalating Threat of Antimicrobial Resistance
  • 3.1.2. Rising Burden of Infectious Disease and Sepsis
  • 3.1.3. Growth of Antimicrobial Stewardship Programs
  • 3.1.4. Technological Advancement Toward Rapid Testing
• 3.2. Market Restraints
  • 3.2.1. Slow Turnaround of Conventional Methods
  • 3.2.2. High Cost of Rapid and Automated Systems
  • 3.2.3. Shortage of Skilled Personnel
• 3.3. Market Opportunities
  • 3.3.1. Rapid Phenotypic Testing and Automation
  • 3.3.2. Emerging Markets and Surveillance Expansion

4. Impact Analysis: AI, Geopolitical, Trade, and Economic Developments

5. Regulatory Analysis

• 5.1. The United States
• 5.2. Europe
• 5.3. Japan
• 5.4. China

6. Antimicrobial Susceptibility Testing Market Porter's Five Forces Analysis

• 6.1. Bargaining Power of Suppliers
• 6.2. Bargaining Power of Consumers
• 6.3. Threat of New Entrants
• 6.4. Threat of Substitutes
• 6.5. Competitive Rivalry

7. Antimicrobial Susceptibility Testing Market Assessment

• 7.1. By Product
  • 7.1.1. Manual Products
  • 7.1.2. Automated Products
  • 7.1.3. Consumables
• 7.2. By Method Type
  • 7.2.1. Disk Diffusion
  • 7.2.2. Dilution
  • 7.2.3. Gradient Diffusion
  • 7.2.4. Automated Testing
  • 7.2.5. Others
• 7.3. By Test Type
  • 7.3.1. Antibacterial
  • 7.3.2. Antifungal
  • 7.3.3. Antiparasitic
• 7.4. By Application
  • 7.4.1. Clinical Diagnostics
  • 7.4.2. Drug Discovery and Development
  • 7.4.3. Epidemiology
• 7.5. By End-User
  • 7.5.1. Hospitals and Diagnostic Laboratories
  • 7.5.2. Pharmaceutical and Biotechnology Companies
  • 7.5.3. Academic and Research Institutes
• 7.6. By Geography
  • 7.6.1. North America
    • 7.6.1.1. United States Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
    • 7.6.1.2. Canada Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
    • 7.6.1.3. Mexico Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
  • 7.6.2. Europe
    • 7.6.2.1. France Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
    • 7.6.2.2. Germany Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
    • 7.6.2.3. United Kingdom Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
    • 7.6.2.4. Italy Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
    • 7.6.2.5. Spain Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
    • 7.6.2.6. Rest of Europe Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
  • 7.6.3. Asia-Pacific
    • 7.6.3.1. China Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
    • 7.6.3.2. Japan Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
    • 7.6.3.3. India Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
    • 7.6.3.4. Australia Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
    • 7.6.3.5. South Korea Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
    • 7.6.3.6. Rest of Asia-Pacific Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
  • 7.6.4. Rest of the World
    • 7.6.4.1. Middle East Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
    • 7.6.4.2. Africa Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
    • 7.6.4.3. South America Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)

8. Antimicrobial Susceptibility Testing Market Competitive Landscape

• 8.1. Competitive Analysis
• 8.2. Company Share Analysis (Premium Offering)

9. Antimicrobial Susceptibility Testing Market Startup Funding and Investment Trends

10. Antimicrobial Susceptibility Testing Market Company and Product Profiles

• 10.1. bioMerieux SA
  • 10.1.1. Company Overview
  • 10.1.2. Company Snapshot
  • 10.1.3. Financial Overview
  • 10.1.4. Product Listing
  • 10.1.5. Strategic Initiatives / Entropy
• 10.2. Becton, Dickinson and Company
  • 10.2.1. Company Overview
  • 10.2.2. Company Snapshot
  • 10.2.3. Financial Overview
  • 10.2.4. Product Listing
  • 10.2.5. Strategic Initiatives / Entropy
• 10.3. Thermo Fisher Scientific Inc.
  • 10.3.1. Company Overview
  • 10.3.2. Company Snapshot
  • 10.3.3. Financial Overview
  • 10.3.4. Product Listing
  • 10.3.5. Strategic Initiatives / Entropy
• 10.4. Danaher Corporation (Beckman Coulter)
  • 10.4.1. Company Overview
  • 10.4.2. Company Snapshot
  • 10.4.3. Financial Overview
  • 10.4.4. Product Listing
  • 10.4.5. Strategic Initiatives / Entropy
• 10.5. Bruker Corporation
  • 10.5.1. Company Overview
  • 10.5.2. Company Snapshot
  • 10.5.3. Financial Overview
  • 10.5.4. Product Listing
  • 10.5.5. Strategic Initiatives / Entropy
• 10.6. Merck KGaA
  • 10.6.1. Company Overview
  • 10.6.2. Company Snapshot
  • 10.6.3. Financial Overview
  • 10.6.4. Product Listing
  • 10.6.5. Strategic Initiatives / Entropy
• 10.7. HiMedia Laboratories Pvt. Ltd.
  • 10.7.1. Company Overview
  • 10.7.2. Company Snapshot
  • 10.7.3. Financial Overview
  • 10.7.4. Product Listing
  • 10.7.5. Strategic Initiatives / Entropy
• 10.8. Liofilchem S.r.l.
  • 10.8.1. Company Overview
  • 10.8.2. Company Snapshot
  • 10.8.3. Financial Overview
  • 10.8.4. Product Listing
  • 10.8.5. Strategic Initiatives / Entropy
• 10.9. Accelerate Diagnostics, Inc.
  • 10.9.1. Company Overview
  • 10.9.2. Company Snapshot
  • 10.9.3. Financial Overview
  • 10.9.4. Product Listing
  • 10.9.5. Strategic Initiatives / Entropy
• 10.10. Bio-Rad Laboratories, Inc.
  • 10.10.1. Company Overview
  • 10.10.2. Company Snapshot
  • 10.10.3. Financial Overview
  • 10.10.4. Product Listing
  • 10.10.5. Strategic Initiatives / Entropy

For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies where relevant to the market assessment.

11. KOL Views

12. Project Approach

13. About DelveInsight

14. Disclaimer and Contact Us